Adipotide
FTPP (Fat-Targeted Proapoptotic Peptide) — chimeric CKGGRAKDC-KLAKLAK peptidomimetic for vascular-targeted white adipose tissue and non-hormonal fat metabolism research
Select size
For research purposes only. Not for human consumption.
Mechanism of Action
Adipotide (FTPP — Fat-Targeted Proapoptotic Peptide) is a synthetic chimeric peptidomimetic linking a CKGGRAKDC targeting sequence — which binds prohibitin on the surface of white adipose tissue vasculature — to a KLAKLAK proapoptotic motif that disrupts mitochondrial membranes. Rather than modulating appetite or metabolism, it selectively induces apoptosis in the endothelial cells feeding white fat depots, causing localized vascular pruning and adipocyte resorption.
How It Works
- 1
Targeting domain (CKGGRAKDC) binds prohibitin selectively expressed on white adipose vasculature
- 2
Proapoptotic domain (KLAKLAK)₂ disrupts mitochondrial membranes upon internalization
- 3
Triggers apoptosis of adipose-supporting endothelial cells, pruning the fat vascular bed
- 4
Results in white adipose tissue resorption without affecting brown fat or lean mass in research models
- 5
Studied for metabolic improvements including insulin sensitivity and leptin normalization
- 6
Non-hormonal, non-stimulant mechanism — distinct from GLP-1 and lipolytic pathways
Key Research Benefits
- Vascular-targeted adipose tissue research
- Prohibitin receptor and tumor-vasculature analog studies
- Proapoptotic peptide (KLAKLAK) mechanism investigation
- Obesity and metabolic syndrome research models
- Non-hormonal fat metabolism pathway exploration
- Comparative research vs GLP-1 agonists and lipotropics
Adipotide was originally developed at MD Anderson Cancer Center by Arap and Pasqualini as an adaptation of tumor-vasculature-targeting peptide technology. Preclinical primate studies demonstrated significant white adipose tissue reduction with metabolic improvements. Strictly research use only — not for human or veterinary administration.